EUVIMEDObjevte EUVIMED
Crossref

Antimigratory and Antiproliferative Effects of the Brain‐Targeted Peptide Conjugate PepH3‐vCPP2319 on Triple Negative Breast Cancer Cell Cultures

Catarina Gonçalves, Miguel A R B Castanho iD, Marco Cavaco iD, Vera Neves

Journal of Peptide Science · 2025-08 · 31 (8)

DOI: 10.1002/psc.70035 ↗

At a glance

Journal article in Journal of Peptide Science, published online on 2025-06-19. Written by Catarina Gonçalves and 3 co-authors. Institution: Instituto de Bioquímica, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. Major MEDLINE topics: Triple Negative Breast Neoplasms, Antineoplastic Agents, Peptides. Cited 2 times so far (Crossref); 54 references. Funded by: "la Caixa" Foundation, Fundação para a Ciência e Tecnologia, 'la Caixa' Foundation.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Triple‐negative breast cancer (TNBC) is an aggressive breast cancer subtype affecting mostly younger women with a poor 5‐year overall survival. It is characterized by a high metastization rate, particularly to the brain, where the blood–brain barrier (BBB) hinders the pharmaceuticals delivery. New anticancer drugs able to inhibit cell migration are required to effectively prevent the development of metastasis. PepH3‐vCPP2319 (AGILKRW(Ahx)WRRRYRRWRRRRRQRRRPRR‐amide), consisting of the conjugation of the BBB peptide shuttle (BBBpS) PepH3 (AGILKRW‐amide) to the anticancer peptide (ACP) vCPP2319 (WRRRYRRWRRRRRQRRRPRR‐amide), was reported to have high anticancer activity (IC 50 = 5.0 μM) toward highly aggressive TNBC cells (MDA‐MB‐231) paired with 2‐fold increased accumulation in the brain when compared to unconjugated vCPP2319. Herein, we demonstrate that PepH3‐vCPP2319 inhibits cell migration and proliferation in wound healing assays, outperforming the gold standard small chemical inhibitor, iCRT‐3. The concentration required to inhibit cell migration is 10‐fold lower for PepH3‐vCPP2319 (0.5 μM) when compared with iCRT‐3 (50 μM). Likewise, PepH3‐vCPP2319 at 2.5 μM was more efficient in preventing cell proliferation when compared with 50 μM iCRT‐3, with 45% reduction in spheroid diameter. This study sheds light on the antimetastatic potential of PepH3‐vCPP2319 through abrogation of cell migration to distant sites, including the brain.

Subjects

MeSH terms (MEDLINE)

Triple Negative Breast NeoplasmsAntineoplastic AgentsPeptidesHumansCell MovementCell ProliferationFemaleCell Line, TumorBlood-Brain BarrierBrain

Author keywords

anticancer peptidescancer metastasiscancer stem cellscell migrationtriple negative breast cancer

Substances

Antineoplastic AgentsPeptides

Authors and institutions

  • Instituto de Bioquímica, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
  • Gulbenkian Institute of Molecular Medicine, Universidade de Lisboa, Lisbon, Portugal.

ORCID profiles: Miguel A R B Castanho, Marco Cavaco

Funding

  • "la Caixa" Foundation
  • Fundação para a Ciência e Tecnologia
  • 'la Caixa' Foundation

Cite

APA

Gonçalves, C., Castanho, M. A. R. B., Cavaco, M., & Neves, V. (2025). Antimigratory and Antiproliferative Effects of the Brain‐Targeted Peptide Conjugate PepH3‐vCPP2319 on Triple Negative Breast Cancer Cell Cultures. Journal of Peptide Science, 31(8). https://doi.org/10.1002/psc.70035

Vancouver

Gonçalves C, Castanho MARB, Cavaco M, Neves V. Antimigratory and Antiproliferative Effects of the Brain‐Targeted Peptide Conjugate PepH3‐vCPP2319 on Triple Negative Breast Cancer Cell Cultures. Journal of Peptide Science. 2025;31(8). doi:10.1002/psc.70035

BibTeX
@article{Gonalves2025,
  author = {Gonçalves, Catarina and Castanho, Miguel A R B and Cavaco, Marco and Neves, Vera},
  title = {Antimigratory and Antiproliferative Effects of the Brain‐Targeted Peptide Conjugate PepH3‐vCPP2319 on Triple Negative Breast Cancer Cell Cultures},
  journal = {Journal of Peptide Science},
  year = {2025},
  volume = {31},
  number = {8},
  doi = {10.1002/psc.70035}
}
Start for free →